Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Event
Portzamparc’s Biotech and Life Sciences Conference
Date : 08/10/2024
Company’s presentation and participation of the management team (virtual event)
Previous Post
October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
Next Post
Investor Access Event
Close Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
MaaT Pharma dans les médias
MaaT Pharma in the News
Devenez membre du club
Become a member of the club